The Federal Reserve made a significant move yesterday by rolling out its third interest rate cut of 2024. This decision was expected to lower borrowing costs across the economy, but it also had some unexpected consequences. Following the announcement, the Dow, S&P, and Nasdaq all experienced a sharp decline due to the Fed’s economic outlook for 2025. The central bank indicated that it only expects two rate cuts in 2025, citing stubbornly persistent inflation and other economic factors.
While the overall market took a hit, biotech stocks were hit even harder. The S&P 500 dropped 3%, the Nasdaq fell 3.6%, and the biotech indexes XBI and SPBIOS were down nearly 5% and over 4.2% respectively. According to Niels Peetz-Larsen from HighVista Strategies, biotech stocks are particularly sensitive to interest rate changes due to their ongoing funding needs.
This news is concerning for biotech startups as well. The rate hikes led to declining investments in the sector in previous years, and even though rate cuts in 2024 led to a slight increase in investment, the investments are currently driven more by fear of missing out than by genuine innovation. Sara Choi from Wing Ventures highlighted the importance of more IPOs and M&A activity to stabilize the biotech market and reduce its reactivity.
However, persistently high interest rates could hinder these efforts and make it more challenging for new breakthrough startups to thrive. Increased borrowing costs can make it expensive for startups to fund research and development, slowing down innovation in the sector. Kazi Helal from Pitchbook also noted that higher interest rates could drive investors toward sectors with more predictable returns, making it harder for biotech startups to secure funding.
Despite these challenges, startups can explore alternative funding options like “biobucks” deals, which involve research collaborations with big pharmaceutical companies. However, Helal warned that higher interest rates could impact the number and terms of these deals, favoring late-stage companies with compelling clinical data.
In conclusion, the current interest rate environment poses significant risks for the biotech industry. If the Federal Reserve decides not to cut rates in 2025, it could further tighten the funding environment, making it harder for startups to secure funding and innovate. This could ultimately delay the development and market entry of crucial disease treatments, impacting patients and the healthcare industry as a whole.
